Any mitochondrial DNA depletion syndrome in which the cause of the disease is a mutation in the FBXL4 gene.
Comprehensive, easy-to-understand information about this condition
How we create this content →Report Generation Failed
We couldn't automatically generate the report. This may be due to temporary service issues.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.
Organizations with orphan designations or approved therapies for this disease
ALTATHERA Pharmaceuticals, LLC
Other
AbbVie Inc.
Other
Anthera Pharmaceuticals, Inc.
Other
Aridis Pharmaceuticals, Inc.
Other
Cephalon, LLC
Other
Eagle Pharmaceuticals, Inc.
Other
Gilead Sciences, Inc.
Other
H. Lundbeck A/S
Other
Hoffmann-La Roche, Inc.
Other
ImmunexImmunex
Other
Incyte Corporation
Other
Lloyd E. King, Jr.
Other
Peter W. Stackpoole, PhD, MD
Other
Pharmacia & Upjohn Company LLC
Other
Pharmacyclics LLC
Other
Pharmaxis Europe Limited
Other
Rejuvenation Therapeutics
Other
SK Life Science, Inc.
Other
Stacpoole, Peter W. M.D., Ph.D.
Other
SuperGen, Inc.
Other
TGV-Inhalonix, Inc.
Other
Ucyclyd Pharma, Inc
Other
Warner-Lambert Company
Other